Artivion, Inc. (AORT) Earnings Call Analysis

NYSE · Healthcare · Medical Devices

19/25

Growth 4 Margin 3 Expansion 5 Platform 3 Financial 4

latest quarter score

Earnings Reports

19
Artivion (AORT) Q2 2026: ONIX Valve Growth Hits 18% as AMDS PMA Approval Unlocks U.S. Acceleration
August 07, 2026
22
Artivion (AORT) Q4 2025: Stent Graft Revenue Jumps 36%, Propelling Double-Digit Growth Outlook
June 16, 2026
19
Artivion (AORT) Q1 2026: EBITDA Margin Expands 130bps as Aortic Arch Portfolio Strategy Advances
May 08, 2026
22
Artivion (AORT) Q3 2025: Stent Graft Revenue Surges 31%, Unlocking High-Margin U.S. Growth
November 07, 2025
21
Artivion (AORT) Q2 2025: ONIX Valve Grows 24%, Driving Margin Expansion and Pipeline Momentum
August 08, 2025
20
Artivion (AORT) Q1 2025: Stent Graft Revenue Jumps 19% as AMDS and Onyx Recovery Fuel Guidance Raise
July 06, 2025
Artivion (AORT) Q3 2024: EBITDA Margin Expands 270bps as Global Portfolio Drives Double-Digit Growth
November 07, 2024
Artivion (AORT) Q2 2024: EBITDA Margin Expands 350bps as On-X and Stent Grafts Drive Double-Digit Growth
August 08, 2024
Artivion (AORT) Q1 2024: EBITDA Margin Expands 480bps as Proprietary Portfolio Drives Global Growth
May 06, 2024
Artivion (AORT) Q4 2023: 72% Mortality Reduction in AMDS Trial Sets Stage for U.S. Market Entry
February 15, 2024
21
Artivion (AORT) Q3 2023: Stent Graft Growth Hits 22% as Clinical Data Drives Market Share Momentum
November 02, 2023
Artivion (AORT) Q2 2023: Stent Graft Revenues Surge 19% as Operating Leverage Expands
August 03, 2023
Artivion (AORT) Q1 2023: ONIX Platform Grows 24%, Fueling Raised Guidance and Margin Leverage
May 04, 2023
Artivion (AORT) Q4 2022: Stent Graft Growth Hits 20% as Supply Chain Stabilizes
February 16, 2023

Browse all companies